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AbsTrACT
The COVID-19 pandemic is putting unprecedented 
pressures on healthcare systems globally. Early insights 
have been made possible by rapid sharing of data from 
China and Italy. In the UK, we have rapidly mobilised 
inflammatory bowel disease (IBD) centres in order that 
preparations can be made to protect our patients and the 
clinical services they rely on. This is a novel coronavirus; 
much is unknown as to how it will affect people with 
IBD. We also lack information about the impact of 
different immunosuppressive medications. To address 
this uncertainty, the British Society of Gastroenterology 
(BSG) COVID-19 IBD Working Group has used the best 
available data and expert opinion to generate a risk 
grid that groups patients into highest, moderate and 
lowest risk categories. This grid allows patients to be 
instructed to follow the UK government’s advice for 
shielding, stringent and standard advice regarding social 
distancing, respectively. Further considerations are 
given to service provision, medical and surgical therapy, 
endoscopy, imaging and clinical trials.
InTroduCTIon
Inflammatory bowel disease (IBD), comprising 
Crohn’s disease (CD) and ulcerative colitis (UC), is 
a condition in which the gastrointestinal immune 
system responds inappropriately. IBD is therefore 
often treated with immunosuppressing medications 
to control inflammation and prevent ‘flares’, a wors-
ening of symptoms, which may be unpredictable.
While it is known that 0.8% of people in the 
UK currently have IBD (approximately 524 000 
patients), only 44% have been to a clinic in the 
past 3 years1 2. There will be many patients who 
are worried about the effect of the coronavirus 
pandemic (SARS- CoV-2 or COVID-19 disease) on 
their IBD and vice versa, many of whom will be 
unknown to secondary care.
During the COVID-19 outbreak, we will do 
everything we can to keep our IBD patients safe. 
The greatest risks relate not only to the infection 
itself, but also the emergency reorganisation of 
hospital and general practice services to deal with 
the pandemic. This will result in significant changes 
to routine IBD services. A combined approach 
covering both primary and secondary care is there-
fore required to keep vulnerable patients with IBD 
out of hospital as much as possible.
Insights from Hubei, China and from Italy 
suggest hospital attendance for non-COVID-19 
illness may provide a reservoir for further spread 
of infection. However, alterations to the way we 
deliver IBD care in the UK must be balanced against 
the risks of under treated, active IBD. Importantly, 
patients with active IBD are likely to have a higher 
risk of infection both in the community and during 
inpatient care, even in the absence of immunosup-
pressive treatment.3 Therefore, it is of paramount 
importance to control intestinal inflammation in 
IBD to prevent adverse outcomes.
CoVId-19 dIseAse And Ibd
The impact of immunosuppression on the severity of 
COVID-19 disease remains unclear. Data reported 
from 1099 Chinese patients with COVID-19 did 
not observe immunodeficiency as a risk factor for 
severe disease (defined according to the Amer-
ican Thoracic Society guidelines for community 
acquired pneumonia).4 The currently understood 
predictors associated with COVID-19 mortality at 
the time of hospital admission are older age (OR 
1.1; 95% CI 1.03 to 1.17 per year increase), higher 
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Table 1 British Society of Gastroenterology inflammatory bowel disease COVID-19 risk grid: Stratification of risk of serious COVID-19 disease into 
highest, moderate and lowest risk categories for patients with inflammatory bowel disease
Highest risk
‘shielding’
Moderate risk
‘stringent social distancing'*
Lowest risk
‘social distancing’
1. IBD patients who either have a comorbidity (respiratory, 
cardiac, hypertension or diabetes mellitus) and/or are ≥70 
years old and† are on any ‘moderate risk’ therapy for IBD 
(per middle column) and/or have moderate to severely active 
disease
2. IBD patients of any age regardless of comorbidity and who 
meet one or more of the following criteria:
 – Intravenous or oral steroids ≥20 mg prednisolone or 
equivalent per day (only while on this dose)
 – Commencement of biologic plus immunomodulator or 
systemic steroids within previous 6 weeks‡
 – Moderate to severely active disease§ not controlled by 
'moderate risk’ treatments
 – Short gut syndrome requiring nutritional support
 – Requirement for parenteral nutrition
1. Patients on the following medications¶:
 – Anti- TNF (infliximab, adalimumab, golimumab, 
certolizumab) monotherapy
 – Biologic plus immunomodulator‡ in stable patients
 – Ustekinumab
 – Vedolizumab
 – Thiopurines (azathioprine, mercaptopurine, tioguanine)
 – Methotrexate
 – Calcineurin inhibitors (tacrolimus or ciclosporin)
 – Janus kinase (JAK) inhibitors (tofacitinib)
 – Immunosuppressive trial medication
 – Mycophenolate mofetil
 – Thalidomide
 – Prednisolone <20 mg or equivalent per day
2. Patients with moderate to severely active disease§ who are 
not on any of the medications in this column
Patients on the following medications:
 ► 5- ASA
 ► Rectal therapies
 ► Orally administered topically acting steroids 
(budesonide or beclometasone)
 ► Therapies for bile acid diarrhoea (colestyramine, 
colesevelam, colestipol)
 ► Antidiarrhoeals (eg, loperamide)
 ► Antibiotics for bacterial overgrowth or perianal 
disease
No specific recommendations are being made regarding IBD and pregnancy, and pregnant women with IBD are encouraged to follow the guidance available from the UK government for pregnant 
women in the general population.
This guidance was last updated by the BSG COVID-19 IBD Working Group on 2 April 2020, and was based on expert opinion and the available evidence at the time.
*The UK government advises those at increased risk, but not reaching the highest risk, of severe illness from coronavirus (COVID-19) to be particularly stringent when applying social distancing 
recommendations.
†That is, at least one of (comorbidity listed above or age ≥70 years) plus at least one of (therapy from middle column or moderate to severely active disease).
‡Patients should be categorised as highest risk (requiring shielding) within 6 weeks of starting biologics if they are on concomitant immunomodulator treatment or systemic steroids, whether 
started simultaneously or prior to the biologic. After 6 weeks they may enter the ‘moderate’ risk category provided they do not meet other highest risk criteria, for example, moderate–severe 
disease not controlled by treatment. Biologic plus immunomodulator in stable patients may increase the risk over monotherapy but there is no specific evidence for this situation.
§As judged by the clinical team responsible for patient care.
¶Patients who have stopped biologics or immunomodulators should remain within their pre- treatment cessation risk category for 3 months; for drugs with a much shorter half- life (eg, tofacitinib), 
we advise clinician discretion.
5- ASA, 5- aminosalicylic acid; IBD, inflammatory bowel disease; TNF, tumour necrosis factor.
sequential organ failure assessment score (OR 5.65; 95% CI 2.61 
to 12.23) and d- dimer >1 µg/mL (OR 18.42; 95% CI 2.64 to 
128.55).5 However, smoking, comorbidity, particularly hyper-
tension, vascular disease, diabetes and male sex have been associ-
ated with poor outcome.4–9 Prolonged illness and complications 
from respiratory infection are perhaps more common when 
non- steroidal anti- inflammatory drugs (NSAIDs) are used, but 
no data in COVID-19 currently exist.10 11 Given NSAIDs have 
also been implicated in IBD flare, paracetamol is advocated as 
firstline analgesia/antipyretic.12
At the time of writing, the Surveillance Epidemiology of Coro-
navirus Under Research Exclusion (SECURE)- IBD registry has 
reported 239 (54% male) cases of COVID-19 in IBD patients 
(137 CD, 94 UC, 5 IBD unclassified), of whom 64 were hospi-
talised and 11 patients died.13 Seven patients underwent venti-
lation. Among the 11 patients who died, a range of medications 
were seen; five patients were receiving mesalazine alone or no 
therapy, although all were aged 69 years or older; four were 
receiving steroids alone or in combination; and the youngest 
patient who died was 33 years and was receiving combination 
therapy with adalimumab, azathioprine and prednisolone.13 The 
British Society of Gastroenterology (BSG), in line with the Inter-
national Organisation for the Study of IBD and the European 
Crohn’s and Colitis Organisation, recommend that patients with 
IBD do not routinely stop their medication to prevent infection 
or adverse outcome with COVID-19.14 15
'Social distancing' (https://www. gov. uk/ government/ 
publications/ covid- 19- guidance- on- social- distancing- and- 
for- vulnerable- people/ guidance- on- social- distancing- for- 
everyone- in- the- uk- and- protecting- older- people- and- vulner-
able- adults) and 'shielding' (https://www. gov. uk/ government/ 
publications/ guidance- on- shielding- and- protecting- extremely- 
vulnerable- persons- from- covid- 19/ guidance- on- shielding- and- 
protecting- extremely- vulnerable- persons- from- covid- 19) are 
measures to reduce spread within the population and to protect 
high risk groups. These are also an understandable source of 
anxiety for patients with IBD.16
On behalf of the BSG, a UK- wide IBD COVID-19 Working 
Group has been established and has defined patient risk as 
highest, moderate and lowest for COVID-19 related poor 
outcome (see table 1 and below for justification of group-
ings). Patients classified as at highest risk, correspond to group 
5 in the UK government’s instruction to undergo ‘shielding’, 
the most stringent form of isolation. The moderate group are 
recommended to be even stricter at following the government’s 
instructions regarding social distancing. Note that all patients 
should still attend for infusions of biologics, irrespective of risk 
stratification.
The UK Department of Health has requested patient contact 
details from local secondary care IBD services for those that 
meet the highest risk. A pragmatic approach to identify individ-
uals within the highest risk group has been adopted:
1. Where feasible, national datasets are being interrogated to 
identify ‘highest risk’ patients.
2. Direct communication with patients via the BSG, and 
Crohn’s and Colitis UK workflows.
3. Patients may self- identify into risk group (https://www. ib-
dregistry. org. uk/ covid- 19) and/or contact their local IBD 
team (ideally by email).
4. Secondary care IBD teams will then provide patient details to 
the National Health Service (NHS).
The self- identification tool (point 3 above) was developed 
using the information in table 1 in partnership with the IBD 
Registry as a pragmatic solution to obtain up to date information 
from UK patients with IBD and maximise the ability to iden-
tify patients in the highest risk group. Early identification and 
intervention (shielding education) to 318 Chinese IBD patients 
in Hubei at risk of COVID-19 was well received by patients and 
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box 1 Top 10 tips for everyone with inflammatory bowel 
disease during the CoVId-19 pandemic
1. We will do everything we can to keep you safe and well 
during the COVID-19 pandemic. Note that hospitals are 
undergoing massive reorganisation to prepare to care for 
those with serious infection.
2. Don’t stop your medication; preventing disease flares is a 
priority. We want to keep you out of hospital if possible, but 
if you are unwell, we will be there for you.
3. Ensure you have a good supply of medication should you 
need to self- isolate or shield yourself. Do not take steroids 
(prednisolone) from your general practitioner without 
discussing with your local inflammatory bowel disease (IBD) 
team.
4. Contact your local IBD team via telephone or email helplines 
if you are experiencing a flare.
5. Wash your hands frequently and avoid touching your face; 
this goes for everyone.
6. Work from home if possible, and avoid non- essential travel 
and contact with people who are currently unwell.
7. Stop smoking, as this increases the risk and severity 
of COVID-19 infection, and avoid non- steroidal anti- 
inflammatory drugs (eg, ibuprofen).
8. Government guidelines on self- isolation and social 
distancing are changing rapidly so please visit www.gov.uk 
and www.nhs.uk to keep up to date. (If you are unclear on 
your level of risk, contact your local IBD helpline for further 
advice).
9. If you, or a household member, develop a continuous cough, 
flu- like symptoms OR fever you should:
a. follow the government's recommendations about self- 
isolation and household quarantine
b. if you test positive for COVID-19 you should contact your 
IBD team
c. stop taking medicines in the middle column of table 1. 
Steroids should be tapered with advice from the IBD 
team and not stopped abruptly. Fourteen days after your 
symptoms have resolved, or if a household member is 
affected, the household quarantine period ends, contact 
your local IBD team for advice regarding restarting your 
medication.
d. if you feel you cannot cope with your symptoms at home, 
or your condition gets worse, or your symptoms do not 
get better after 7 days, then use the NHS 111 online 
coronavirus service. If you do not have internet access, call 
NHS 111. For a medical emergency dial 999.
10. Take care of yourself but also be kind and considerate to 
others in these difficult times.
may have protected them from infection, with none of them 
reporting infection, as of 28 February 2020.17
At the time of writing, there is a lot of activity at UK govern-
ment level around the wearing of masks by the general popu-
lation in public spaces and hospitals. The BSG recommends 
members of the public to follow the most up to date advice from 
the government with respect to this.
Most IBD patients will fall into the moderate or lowest risk 
groups. Defining a ‘highest risk’ group is not exact, with little or 
no evidence specific to COVID-19. The grouping has therefore 
been determined following extensive discussion among UK IBD 
specialists with input from international colleagues. Based on the 
current evidence, we understand increasing age, heart disease, 
diabetes and hypertension are the among the greatest risk factors 
for poor outcome in COVID-19.4–9 As such, priority has been 
given to these factors alongside medications, other than indi-
viduals on high dose steroids (table 1 and below). Where risk is 
primarily determined by IBD (patient and treatment factors), we 
recognise this is a dynamic process—that is, patients may move 
between risk categories over the duration of the pandemic.
This is a very busy time for clinical teams with redeployment 
in order to manage the COVID-19 pandemic. We have there-
fore aimed for simple clear messages wherever possible. For 
this reason, we have deliberately not provided a drug by drug 
description of clearance, and recommend it is 3 months after 
cessation of a drug therapy before a patient changes risk cate-
gory. In part, this is to discourage the practice of stopping drugs 
purely to switch risk category. The exception is steroids, which is 
covered explicitly in the grid. As a working group, we have had 
some discussion about tofacitinib which has a much shorter half- 
life; in this case, we advise clinician discretion regarding the time 
point at which cessation impacts on risk categorisation.
We wish to strongly emphasise:
 ► Patients should continue their current medications.
 ► Access to injectable treatment (infliximab, vedolizumab, 
ustekinumab, adalimumab, certolizumab and golimumab) 
should be maintained, irrespective of risk category and 
distancing/isolation recommendations.
 ► Infusion suite services (with appropriate social distancing 
methods) should be maintained as a priority area to 
prevent treatment flare, admission and increased risk of 
immunogenicity.
 ► Home care provision of subcutaneous medicines should be 
maintained as a priority for IBD patients.
General advice for all IBD patients is provided in box 1.
CHAnGes To CurrenT prIMAry And seCondAry CAre 
prACTICes
Hospital services are being reorganised to better deal with severe 
COVID-19 infections. Elective work is being suspended to maxi-
mise staffing and space for acute admissions. We also need to be 
very careful that rapid institution of telemedicine services does 
not adversely impact on primary care (eg, phlebotomy and drug 
prescribing).
Consideration should be given to reorganising services to 
support well staff working from home when possible, to mini-
mise their own viral exposure. Staff sickness is likely to become a 
major factor during this pandemic and so efforts should be made 
to minimise this from the earliest stages.
Pre- symptomatic transmission has been reported, although 
estimated rates vary between studies. Face to face meetings 
between staff, particularly in confined spaces, should be mini-
mised and, where necessary, should avoid people being in close 
proximity if possible. Services such as Microsoft Teams (https:// 
teams. microsoft. com), WebEx (https://www. webex. com) and 
Zoom (https:// zoom. us) can be used to facilitate virtual meet-
ings (see also https://www. ecdc. europa. eu/ sites/ default/ files/ 
documents/ RRA- sixth- update- Outbreak- of- novel- coronavirus- 
disease- 2019- COVID- 19. pdf).
Ibd nurse phone and email helpline
To manage and support patients with IBD when outpatient 
clinics are being converted to telephone review, the minimum 
service provision needs to include a telephone/email helpline 
to support patients having disease flares and to answer queries 
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regarding immunosuppressant/biologics management. Ideally, 
provision should be made for one member of the nursing team to 
work from home to ensure this is maintained, with appropriate 
senior review to support the clinical decision making process. 
This would reduce the burden on both primary and secondary 
care, in particular the accident and emergency department. This 
should be supported with capacity for patients to have urgent 
review if needed in a ‘safe clinic’.
Patients are being asked to keep taking their usual IBD therapy. 
If patients stop taking their medications without discussing it 
with their clinical team first, there is a risk of disease flare. Active 
disease is associated with an increased risk of infection, exposure 
to steroids (increased risk from infection), hospitalisation and 
major surgery.3 18
outpatient clinics
Conduct clinical appointments by telephone or a formal tele-
medicine system where possible. Routine bloods may be 
deferred until the situation has improved, depending on local 
capacity. Access to faecal calprotectin (FC) testing, a potential 
alternative to endoscopy, may become limited due to the pres-
ence of virus in the stool. If accessible, consider introduction of 
point of care calprotectin testing. FC point of care kits could be 
most effectively issued to high risk patients at a new patient/flare 
clinic or on discharge from hospital (sampling every 2–3 months 
depending on capacity). Given the limited access to endoscopic 
disease assessment, the combination of FC and clinical disease 
scores (eg, partial Mayo/Simple Clinical Colitis Activity Index, 
Paediatric Ulcerative Colitis Activity Index, Harvey–Bradshaw 
index or weighted Paediatric Crohn's Disease Activity Index) 
may help to guide treatment decisions more objectively.
new Ibd patients
In line with the Joint Advisory Group/BSG endoscopy guid-
ance released on 26 March 2020, all non- emergency endoscopy 
should stop immediately. Careful case by case discussion will 
need to be given to decide the timing of diagnostic endoscopy 
for the most urgent suspected new IBD cases. If centres are 
delayed in assessing new IBD patients, a telephone triage system 
should be adopted to assess clinical urgency.
urgent outpatient review
Patients who may require hospitalisation will need to continue 
to be assessed in a timely manner. Consider the most appropriate 
location to do this that is away from COVID-19 assessment areas. 
Daily ‘flare clinics’ (virtual where possible) with limited numbers 
of patients who are at high risk of imminent hospitalisation 
should be considered. Where possible, limit visits to hospital and 
limit the patient journey around the hospital geographically.
GenerAL ConsIderATIons reGArdInG Ibd MedICATIons
 ► Balance the risk of immune modifying drugs with the risk 
associated with active disease.
 ► Patients are advised not to stop or reduce their medication 
without discussing with the IBD team, due to the risk of flare 
leading to a need for steroids or other additional immuno-
suppression or hospitalisation.
 ► Immunosuppressive effects of medications may persist for 
many weeks or months after treatment cessation.
 ► Identify an experienced/senior person to oversee blood 
tests, initiation of biologics and prescribing of biologics, and 
support patients accordingly. Reduce any therapy associated 
monitoring blood tests to a minimum safe frequency.
 ► Administrative support should be identified to ensure 
prescriptions for subcutaneous biologics are forwarded to 
home care in a timely manner.
 ► Patients should be given helpline details to arrange contact 
for advice regarding delayed deliveries.
 ► Maintaining a functional infusion service throughout the 
pandemic should be a priority.
THerApy speCIfIC ConsIderATIons
Given the paucity of data regarding the effects of IBD medica-
tions on the course of COVID-19, contributing confirmed cases 
to the international registry (SECURE- IBD, https:// covidibd. org) 
is encouraged.
 ► Corticosteroids
 – Should be avoided if possible but will still be necessary 
for some who should then observe 'shielding’ while pred-
nisolone dose is ≥20 mg daily.
 – High dose steroids are an established risk factor for respi-
ratory tract infection and opportunistic infection in IBD 
and septicaemia.19 20
 – Rapid tapering (10 mg/week) should be considered 
where possible. This must be balanced against the risks 
of extending steroid exposure overall by decreasing dose 
too quickly.
 – Should not be stopped suddenly without advice.
 – Consider using budesonide MMX (9 mg/day 8 weeks) or 
beclometasone (5 mg/day 4 weeks) for patients with flar-
ing UC (important to assess after 2 weeks).
 – Consider using exclusive enteral nutrition for patients 
with flaring CD.
 – Consider budesonide (Entocort, Budenofalk, 9 mg/day 
8 weeks) for active small bowel and ileo- caecal CD.
 ► Immunomodulators (azathioprine, mercaptopurine, tiogua-
nine, methotrexate, tacrolimus, mycophenolate mofetil)
 – No current evidence of increased risk of COVID-19 
infection.
 – Initiation of monotherapy may not be appropriate.
 – Combination therapy with biologics should be made on 
careful discussion of risk and benefit on a case by case 
basis.
 – Older patients (>60 years) or those with significant co-
morbidity who are in sustained remission on thiopurines 
may wish to consider stopping after appropriate discus-
sion with their IBD team.
 ► Anti- tumour necrosis factor therapy (adalimumab, inflix-
imab, golimumab, certolizumab)
 – No current evidence of increased risk of COVID-19 
infection.
 – Consider initiation with monotherapy (therefore consid-
er adalimumab to promote home care and lower risk of 
immunogenicity relative to infliximab).
 – Use early therapeutic drug monitoring where possible, 
highlighting those appropriate for later combination im-
munosuppression where necessary.
 – Enforced intravenous to subcutaneous switching is not 
recommended.
 ► Anti- interleukin-12/23p40 therapy (ustekinumab)
 – No current evidence of increased risk of COVID-19 
infection.
 – One advantage of ustekinumab is a one off intravenous 
induction dose followed by subcutaneous maintenance 
dosing (minimal impact on infusion suite).
 ► Anti-α4β7 integrin therapy (vedolizumab)
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 – No current evidence of increased risk of COVID-19 
infection.
 – Unlikely to increase the risk of COVID-19 complica-
tions, although caution should be exercised in applying 
existing trial data to COVID-19.
 ► Janus kinase inhibitors (tofacitinib)
 – No current evidence of increased risk of COVID-19 
infection.
 ► 5- Aminosalicylic acid derivatives (mesalazine)
 – No current evidence of increased risk of COVID-19 
infection.
 – In UC patients with uncontrolled symptoms, oral 
5- aminosalicylic acid dose should be optimised with or 
without the addition of topical (rectal) 5- aminosalicylic 
acid.
serVICe ConsIderATIons
Remote monitoring of disease activity can be achieved through 
virtual clinics using blood tests taken at sites remote to the 
hospital (eg, satellite facilities or via a general practitioner), 
with standard laboratory or point of care FC monitoring where 
available.
The infusion service is a priority area. Consider moving off 
site to a ‘clean’ area if possible or facility with alternative access, 
avoiding the need to pass through the main hospital. Visitors 
should no longer be permitted. Patients should not attend for 
infusion if they are symptomatic for COVID-19 and where 
possible should be screened on arrival for symptoms and fever. 
Two metre spacing should be employed between patients, and 
there should be a dedicated separate waiting area if possible. A 
strict hand washing policy on arrival should be enforced. Infu-
sion chairs should be appropriately cleaned between patients. 
Parenteral electrolyte and iron replacement services should be 
reserved for urgent cases only. If capacity is reduced due to staff 
shortages, daily/weekly triage of infusions should take place.
endoscopy
The BSG has provided separate guidance on endoscopy and 
COVID-19 (https://www. bsg. org. uk/ covid- 19- advice/). IBD 
surveillance procedures should be deferred. IBD disease assess-
ment scopes will need to be carefully assessed for priority. 
Alternative methods of disease assessment, including the use 
of biomarkers, radiology and capsule endoscopy should be 
considered.
Imaging
The capacity for outpatient imaging may be reduced. However, 
this should be discussed within individual hospitals. Access to 
different imaging modalities may vary during the pandemic and 
this may influence the choice of investigation for patients with 
IBD.
surgery
Routine elective operations have been deferred in most centres. 
Where possible, urgent management of perianal sepsis should 
be undertaken as a day case procedure. Complex IBD surgery 
should be deferred where possible and its timing should be 
reviewed regularly at multidisciplinary meetings. Emergency 
procedures (e.g. subtotal colectomy in acute severe UC, intestinal 
resection to control penetrating disease in CD) will continue as 
part of routine care. As with active disease, the choice of postop-
erative therapy to prevent recurrence will need to be considered 
in the context of the COVID-19 pandemic. If surgery is required 
for subacute obstructive symptoms, it may be possible to avoid 
or delay surgery by using partial or exclusive enteral nutrition 
regimens.21
Clinical trials
The National Institute for Health Research (NIHR) and Chief 
Scientist Office (CSO) have produced guidance on the manage-
ment of clinical trials which will be updated regularly (NIHR 
https://www. nihr. ac. uk/ news/ dhsc- issues- guidance- on- the- 
impact- on- covid- 19- on- research- funded- or- supported- by- nihr/ 
24469; CSO http://www. nhsresearchscotland. co. uk/ news/ covid- 
19--- guidance- for- sponsors- sites- and- researchers). Many trials 
will have already been paused by their sponsors.
Where this has not happened, participant screening, recruit-
ment and continuation (for participants already recruited) 
should be reviewed at the local level for appropriateness in 
the current clinical situation. The benefits of avoiding surgery 
and/or corticosteroids by receiving trial medication that may 
not be otherwise available must be balanced against the risk 
of face to face visits and the unknown effects of the investiga-
tional medicinal product on the course of COVID-19. Where 
possible, trial visits should occur virtually, and investigations that 
require hospital attendance should be postponed unless clinically 
important. Protocol amendments should be made to the relevant 
regulatory bodies, and advice should be sought from research 
and development directors promptly to protect participants, as 
formal approval may be significantly delayed. Blinded trials pose 
a particular concern; principal investigators should be prepared 
to unblind participants where the information will influence the 
participant’s treatment or when assessment and management of 
coronavirus is being considered. In addition, patients who may 
be on a placebo medication that does not require self- isolation 
or social distancing should have this highlighted to them in case 
they wish to withdraw from a study. Sponsors should consider 
minimising the burden of administrative tasks while healthcare 
teams are stretched; many members of the research team are 
already being redeployed into direct clinical care.
AdVICe for nHs sTAff wITH Ibd
Frontline staff with IBD should follow the same precautions as 
other IBD patients. However, given the high risk of exposure 
of frontline staff to SARS- CoV-2, it would be advisable that 
hospital teams consider utilising team members with IBD in roles 
where exposure is limited (i.e. telephone clinics as opposed to 
endoscopy lists and ward work), especially if that individual is 
at 'moderate’ risk or has other comorbidity, in which case they 
should be supported in working from home if possible. If it 
is essential for them to work in a hospital environment, they 
should ensure they avoid close contact with other staff members 
and can maintain social distancing.
ConCLusIon
The COVID-19 pandemic has posed unprecedented challenges 
to healthcare providers across the globe. The IBD community 
must continue to demonstrate adaptability in this rapidly moving 
field. Collaborative working is vital to ensure we gather as much 
knowledge as possible collectively, sharing ideas to provide the 
best outcomes for our patients as new evidence emerges.
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